Objective Review bilirubin pathway or metabolism

38
Objective 1.Review bilirubin pathway or metabolism 2.Explore risk factor for neonatal jaundice 3.Outline causes of indirect hyperbilirubinemia 4.Outline causes of jaundice in 1 st 24 hr of life and that persist more than 2-3 week 5.Distinguish between physiological vs pathological jaundice 6.Distinguish between breast milk vs breast feeding jaundice 7.Be able to diagnose kernicterus , discover risk factor and make prevention 1

description

Neonatal jaundice Yellowish discolouration of skin and sclera because of increase serum level of bilirubin indirect (unconjucated ) or direct (conjucated ) occur in 60% of term infant & 80% of preterm infant

Transcript of Objective Review bilirubin pathway or metabolism

Page 1: Objective Review bilirubin pathway or metabolism

Objective 1. Review bilirubin pathway or metabolism

2. Explore risk factor for neonatal jaundice

3. Outline causes of indirect hyperbilirubinemia

4. Outline causes of jaundice in 1st 24 hr of life and that persist more than 2-3 week

5. Distinguish between physiological vs pathological jaundice

6. Distinguish between breast milk vs breast feeding jaundice

7. Be able to diagnose kernicterus , discover risk factor and make prevention

1

Page 2: Objective Review bilirubin pathway or metabolism

• Yellowish discolouration of skin and sclera because of increase serum level of bilirubin

• indirect (unconjucated ) or • direct (conjucated )• occur in 60% of term infant & • 80% of preterm infant

2

Page 3: Objective Review bilirubin pathway or metabolism

3

• Bilirubin derived from of heme containing proteins

• 75% of heme from senescent RBC Hb in RE system

• 25% of heme from Hb of ineffective erythropoiesis in the BM & from myoglubin , cytochromes , catalase & free heme .

Page 4: Objective Review bilirubin pathway or metabolism

4

Page 5: Objective Review bilirubin pathway or metabolism

5

• Heme oxidized by heme oxygenas biliverdin which

• reduced by biliverdin reductase indirect (unconjucated)

bilirubine which is water insoluble (not excreted in urin )

• bind to albumin. This albumin binded bilirubin is not

toxic to CNS .

• When binding sites become saturated with bilirubin if

• free unconjucated bilirubin high or

• competative compound as sulfonamide , & FFA ,these will

lead to increase free bilirubin which may enter CNS &

causing toxicity & kernicterus

Page 6: Objective Review bilirubin pathway or metabolism

6

indirect bilirubin dissociated from albumin at hepatocyte where bound

to cytoplasmic ligandin (Y protein ) for transport to smooth

endoplasmic reticulum

( phenobarbitone increase ligandin in endoplasmic reticulum that decrease bilirubin ).Conjucation will occur in liver when indirect bilirubin converted by

UDPGT (Uridin Diphosphate Glucuronyl Transferase) forming

direct bilirubin ( monoglucuronide & diglucuronide ) which is water

soluble capable of biliary & renal excretion .

UDPGT & ligandin is lower in the new born

( especially preterm ) that increase bilirubin .

Page 7: Objective Review bilirubin pathway or metabolism

7

Conjugated bilirubin is excreted by the biliary tree & enters GIT

where some of it metabolised by colonic bacteria to form urobilinogen and then stercobilinogen, which may be further oxidized to stercobilin that give feces its brown color.

some of the urobilinogen is reabsorbed & excreted in the urine where some of it further oxidize to urobilin which gives urine it characteristic color

*

Page 8: Objective Review bilirubin pathway or metabolism

8

Some of the conjugated bilirubin in GIT may be reconverted to unconjugated bilirubin by intestinal bilirubin glucuronidase then again reabsorbed go back to liver ,this is called enterohepatic circulation . That increase indirect bilirubin

Enterohepatic circulation increase in some new born & in patients with pyloric stenosis, intestinal Atresia, meconium ileus , Hirschprung`s disease & decrease oral intake . but it decreased by intestinal bacteria

Page 9: Objective Review bilirubin pathway or metabolism

Risk Factors for Development of Severe Hyperbilirubinemia in Infants of 35 or More Week's Gestation

Major risk factors►Jaundice observed in the first 24 hr

► Blood group incompatibility, other hemolytic disease

► Gestational age 35–36 wk

► Previous sibling received phototherapy

►Cephalohematoma or significant bruising

►Exclusive breast feeding, if nursing is not going well

and weight loss is excessive

►East Asian race 9

Page 10: Objective Review bilirubin pathway or metabolism

 Risk Factors for Development of Severe Hyperbilirubinemia in Infants of 35 or More

Week's Gestation Minor risk factors►Gestational age 37–38 wk

► Jaundice observed before discharge

► Previous sibling with jaundice

► Macrosomic infant of a diabetic mother

► Maternal age ≥25 yr

► Male gender

10

Page 11: Objective Review bilirubin pathway or metabolism

 Risk Factors for Development of Severe Hyperbilirubinemia in Infants of 35 or More

Week's Gestation Decreased risk

►Gestational age ≥41 wk

► Exclusive bottle feeding

► Black race

11

Page 12: Objective Review bilirubin pathway or metabolism

12

1. Physiolgical jaundice ( most common )2. Breast milk jaundice3. Over production (hemolysis ) include :-

Blood group incomp. ( Rh , ABO , subgroup as kell, Duffy )RBC enzyme defect as G6PD deficiency , pyruvate kinase deficiency.Herditory spherocytosis, elliptocytosis Hb pathy (alpha thalasemia )Acquired hemolysis (infection , drug vit K sulfonamide )Extravascular bleeding as (peteache , hematoma , pulmonary cerebral ,or occult hemorrhage Polycythemia as materno-fetal or feto-fetal transfusion , delay clamping of umbilical cord .

Page 13: Objective Review bilirubin pathway or metabolism

13

4.Increase enterohepatic circulation as pyloric stenosis , meconium plug syndrom , hirschsprung disease , intestinal atresia or stenoses including annular pancreas, fasting or hypoperistalses, drug induce paralytic ileus, swallowed blood .

5.damages or reduces the activity of the transferase enzyme or other related enzymes (hypoxia, infection, thyroid deficiency , genetic deficiency as Crigler najjar , also inhibition of conjugation by drug

6.Decrease bilirubin uptake across hepatocyte due to competitive inhibition as drug or breast milk jaundice. Miscellaneous as hypothyroidism , hypoxia, acidosis

7.Miscellaneous as sepsis, UTI ,hypoglycemia , infant of diabetic mother .

8.drug such as oxytocin

Page 14: Objective Review bilirubin pathway or metabolism

It is the most common cause of jaundice in the neonatal period ,

it is usually appear in2nd or 3rd day of life in full term infant & 3rd or 4th day in premature

Level reach Peak usually (6-8 mg/dL ) & not > 12 mg / dL in 3rd day in full term and usually (10-12 mg/dL) & not > 15 mg/dL in 5th day in preterm .

14

Page 15: Objective Review bilirubin pathway or metabolism

usually disappear by 4 – 5 days ( rarely by 7 -10 days ) in full term & usually by 7 - 9 days ( rarely by 10 days - 2wk ) in preterm .

Increase of bilirubin should be not > 5mg/dL/ 24 hr or not > o.5 mg/dL/hr

15

Page 16: Objective Review bilirubin pathway or metabolism

16

causes g increase production of bilirubin due to increase RBC

volume per kilogram & decrease RBC survival (70-90 ) days in infant versus 120 days in adult . and also increase ineffective erythropoiesis and increase turn over of non hemoglobin heme proteins .

g increase enterohepatic circulation by high level of intestinal glucuronidase, decrease intestinal bacteria , decrease gut motility with poor evacuation of bilirubin laden meconium .

g defective uptake of bilirubin from plasma by decrease ligandin

g defective conjucation due to decrease of UDPG-Tg decrease hepatic excretion of bilirubin .

Page 17: Objective Review bilirubin pathway or metabolism

17

Physiological jaundic may be exaggerated ( increase peak & duration )

• when there is a risk factors as ; breast feeding , male sex , cephal hematoma , cutanouse bruising , polycythemia , weigh loss , dehydration , caloric deprivation , delay bowel movement , maternal DM , drug ( K3 , novobiocin oxytocin ), trisomy

Page 18: Objective Review bilirubin pathway or metabolism

• Treatment • Self limiting• Ensure feeding• Good follow up of jaundice and TSB level for

abnormal increase or abnormal clinical finding that indicate pathological jaundice

18

Page 19: Objective Review bilirubin pathway or metabolism

The jaundic should not regarded as physiological and should regarded as pathological and should be investigated if It appeare in the 1st 24 houre

TSB increasing > 5mg/dL/ 24 houre or > o.5 mg/dL/houre

TSB >12 mg /dL in full term or >14mg/ dL in preterm .

Duration of jaundice > 10-14 days

Jaundice appears excessive for infant's age or rising rapidly crossing percentiles

Direct B >2 mg/ dL or pale stool, dark urin +ve bilirubin.

19

Page 20: Objective Review bilirubin pathway or metabolism

Cont. Sick infant or associated with vomiting

lethergy poor feeding Weigh loss, apnea bradycardia hypothermia or When there is pallor ,Hsmegally ,

sign of kernicterus ,

family History of hemolytic disease , TSB concentration approaching exchange

levels or not responding to phototherapy jaundice present at or beyond age 3 wk

20

Page 21: Objective Review bilirubin pathway or metabolism

21

Jaundice in the 1st 24 hours 1. Erythroplastosis fetalis (hemolysis); ABO & Rh .

other cause of hemolysis as G6PD , PK def , spherocytosis

2. Concealed hemorrhage (cephal haematoma ,hepatic & spleenic - hemorrhage

3. Sepsis .4. Congenital infection (CMV, Rubella, Toxoplasmosis

5. Crigler najjar

Page 22: Objective Review bilirubin pathway or metabolism

22

Prolonged jaundice duration more than 2 weeks & may persist in and beyond 1st

month (pathological ) causes include

1. Hemolysis2. Hypothyroidism 3. Crigler najjar 4. Breast milk jaundice .5. Intestinal obstruction , Pyloric stenosis 6. idiopathic neonatal hepatitis7. Hyperalimentation .8. Hepatitis, CMV, Syphilis & toxoplasmosis ,

TORCH9. Galactossaemia .10.Biliary atresia .11.Inspissated bile syndrome follow hemolytic

Page 23: Objective Review bilirubin pathway or metabolism

23

► one of the causes of prolonged neonatal unconj hyperB .► when patient may or may not has as physiological jaundice at

beginning develop significance elevation of bilirubin between 1st & 2nd week (usually after 7th day ) of life reach maximum10-30 mg/ dL ( rarely more than 20 mg/dL ) during 2nd-3rd week.

► The cause is unclear but in some the milk contain glucuronidase, that increase enterohepatic circulation .

► if breast feeding continue the jaundice persist for 3-10 weeks at lower level ,

► if we stop breast feeding there is rapid decrease reach normal within few days with out return when re-start breast feeding

Page 24: Objective Review bilirubin pathway or metabolism

24

• Befor Dx of BMJ we have to exclude other causes of unconj hyperB as hemolysis ,hypothyroidism , sepsis .

• treatment , stop breast feeding for 1-2 days . • some times phototherapy may be needed, • very rarely kernicterus has been reported• This breast milk jaundice should be distinguished

from breast-feeding jaundice

Page 25: Objective Review bilirubin pathway or metabolism

breast-feeding jaundice

• early-onset, exaggerated phyasiolgical unconjugated hyperbilirubinemia, in 1st week of life, in breast-fed infants which may be due to

• decreased milk intake with dehydration and/or reduced caloric intake.

• giving glucose water (low calories ).• Prevented & reduce by frequent breast-feeding , night

feeding, discouraging 5% dextrose or water supplementation .

25

Page 26: Objective Review bilirubin pathway or metabolism

26

Familial Non Haemolytic Uncojucated Hyperbilirubinaemia :

( inherited deficient conjugation of bilirubin )

• It is a group of inherited disease associated with different degrees of decrease in hepatic UDPG-T

• Crigler Najjar type 1 syndrome abscence enzyme • Crigler Najjar type 2 syndrome partial defect in

hepatic enzyme

Page 27: Objective Review bilirubin pathway or metabolism

27

Rare , transmitted as AR clinically presented with severe unconj. Hyperbilirubinaemia with no hemolysis , develop in 1st 3 days of life which may reach 25 – 35 mg /dL during the 1st month & may continue after that . kernicterus is a common complication .

Page 28: Objective Review bilirubin pathway or metabolism

28

► Highe level of unconj. Bilirubin with no hemolysis

► No rseponse to phenobarbitone ( differentiated from type 2 )

► Definitive Dx is established by measuring hepatic glucuronyl

transferase activity in liver specimen .

► DNA Dx .

Page 29: Objective Review bilirubin pathway or metabolism

29

► Neonatal period may need continuous phototherapy &

repeated exchange transfusion to prvent K . Even after neonatal period

► Cholestyramine or agar used to bind photobilirubin product & thus interfere with enterohepatic circulation .

► Rx of infection or any illness to prevent development of K ► Plasmaphoresis ► Metacloporphyrin can used to prevent heme oxygenase. ► Genetic engineered enz. Replacement ► hepatic transplant cure disease .► Liver direct gene therapy

Page 30: Objective Review bilirubin pathway or metabolism

30

It is AR , partial defect in hepatic UDPG-T, may be

present similar to Type 1 or may be less severe even

occasionally without neonatal manifestation .

TSB range may compatible with physiological or

pathological level ,

Kernicterus is unusual

Jaundice respond dramatically to phenobarbital

Page 31: Objective Review bilirubin pathway or metabolism

31

• K. is a neurological syndrom result from the deposition of indirect B. in the brain cell especialy basal ganglia . when B. exceed B. Binding capacity of albumin ,free B. will cross B.B.B & diffuse to brain cell & cause cell damage & K.

• The precise level of indirect B. which is toxic to the brain & duration of exposure was unknown

• K is unusual & rare in healthy full term at B.< 25 mg/dL with no hemolysis .

Page 32: Objective Review bilirubin pathway or metabolism

32

There is some risk factor that increase possibility of K. at lower level of B.which may damage B.B.B. or decrease B. binding

capacity of albumin as

• Hemolysis , hyperosmolality , IVH acidosis, hypoalbuminemia , FFA , hypothermia, drug ,hypoglycemia, hypoxia , sepsis, asphyxia , meningitis , prematurity

• so for example premature LBW infant develop K. at lower B. level than 20-25 mg/dL or even 10mg/dL in VLBW.

Page 33: Objective Review bilirubin pathway or metabolism

33

g Onset usually in the 1st wk of life, Signs & symptoms of K. usually appear at 2 –5 days in full term & 7th day in premature but it can occur at any time in neonatal period .

g The early signs include poor feeding , lethargy , loss of moro reflex , hypotonia ,high pitch cry , irritability .

g These signs are usually indistinguishable from sign of sepsis , asphyxia , hypoglycemia & intracranial Hemorrhage . early

Page 34: Objective Review bilirubin pathway or metabolism

Then 2–3 days after the initial phase at end of 1st week & 2nd week the patient become severly ill , respiratory distress , bulging fontanelle , hypertonia , opisthotonos, retrocollis, shrill high pitch cry , convulsion .

34

Page 35: Objective Review bilirubin pathway or metabolism

35

g Many infant who reach this stage are die & most of survival uaually develop later complete neurological syndroms but may appear to recover for 2–3 month (appear with little abnormality )

g Later in the 1st year opisthotonos , muscle rigidity , irreguler movement , hypertonia , & convulsion .

Page 36: Objective Review bilirubin pathway or metabolism

36

g Then gradual develoment of complete neurological syndrom which include

g chorioathetosis , involuntary muscle spasm , extrapyramidal signs , fit , MR , dysarthritic speech , deafness , spastic quadriplegia , teeth discoloration , enamel dysplasia .

Page 37: Objective Review bilirubin pathway or metabolism

PREVENTION. • Early Screening and follow-up any newborn after delivery

and after discharge for hyperbilirubinemia & presence of

risk factors by Hx , examination and lab on need

• early measurment & follow up of serum bilirubin level in

any jaundiced neonate treatment accordingly.

• avoid (visual) assessment but ( by lab )

• 1st 24 hr jaundiced must evaluated for possible hemolytic

disease .

37

Page 38: Objective Review bilirubin pathway or metabolism

PREVENTION.

Parental communication about infant's skin color & education about potential risks and neurotoxicity

Mothers should be advised to nurse infant every 2–3 hr in order to ensure adequate hydration and caloric intake

avoid supplementation glucose and water Treatment of condition that increase risk of K. like sepsis ,

acidosis , asphyxia ,IVH ….etc . Prevention of Rh isoimmunization where Any pregnant

Rh –ve woman giving her human Anti D globuline when she delivered Rh +ve baby or develop abortion.

38